Table 5. Association between polymorphisms of estrogen metabolism-related genes and the risk of prostate cancer, by Gleason score and clinical stage, for the native African population.
| Gleason Score | Clinical Stage | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Low Grade | High Grade | Localized | Advanced | ||||||
| Controls n (%) | Cases n (%) | Adjusted OR a (95% CI) | Cases n (%) | Adjusted OR a (95% CI) | Cases n (%) | Adjusted OR a (95% CI) | Cases n (%) | Adjusted OR a (95% CI) | |
| CYP17 (rs743572) | |||||||||
| T (A1) | 182 (60.7) | 65 (60.2) | 1.0 | 103 (60.6) | 1.0 | 102 (60.0) | 1.0 | 81 (61.4) | 1.0 |
| C (A2) | 118 (39.3) | 43 (39.8) | 1.08 (0.67–1.75) | 67 (39.4) | 1.08 (0.70–1.66) | 68 (40.0) | 1.10 (0.72–1.68) | 51 (38.6) | 1.01 (0.64–1.60) |
| CYP19 (rs60271534) | |||||||||
| ≤7 | 240 (81.6) | 88 (86.3) | 1.0 | 136 (80.0) | 1.0 | 136 (81.0) | 1.0 | 106 (82.8) | 1.0 |
| >7 | 54 (18.4) | 14 (13.7) | 0.68 (0.35–1.32) | 34 (20.0) | 1.03 (0.60–1.7-) | 32 (19.0) | 0.94 (0.55–1.60) | 22 (17.2) | 0.82 (0.45–1.49) |
| CYP1B1 (rs1056836) | |||||||||
| G (Val) | 251 (83.7) | 93 (86.1) | 1.0 | 141 (82.9) | 1.0 | 147 (86.5) | 1.0 | 105 (79.5) | 1.0 |
| A (Leu) | 49 (16.3) | 15 (13.9) | 0.78 (0.41–1.50) | 29 (17.1) | 0.88 (0.51–1.54) | 23 (13.5) | 0.71 (0.40–1.26) | 27 (20.5) | 1.10 (0.63–1.94) |
| COMT (rs4680) | |||||||||
| G (Val) | 196 (70.5) | 92 (85.2) | 1.0 | 130 (76.5) | 1.0 | 137 (81.5) | 1.0 | 99 (75.0) | 1.0 |
| A (Met) | 82 (29.5) | 16 (14.8) | 0.35 (0.19–0.65) | 140 (23.5) | 0.63 (0.38–1.02) | 131 (18.5) | 0.45 (0.27–0.75) | 33 (25.0) | 0.68 (0.41–1.14) |
| UGT1A1 (rs8175347) | |||||||||
| ≤ 6 | 155 (52.7) | 57 (55.9) | 1.0 | 57 (55.9) | 1.0 | 66 (51.6) | 1.0 | 90 (53.6) | 1.0 |
| > 6 | 139 (47.3) | 45 (44.1) | 0.86 (0.54–1.39) | 45 (44.1) | 1.06 (0.69–1.62) | 62 (48.4) | 0.94 (0.62–1.42) | 78 (46.4) | 1.00 (0.64–1.57) |
a Adjusted for age for CYP17 and COMT; for age, BMI and alcohol consumption for CYP19; for age and education for CYP1B1 and for UGT1A1.